The business of psychedelics: Wall Street backs a new class of drugs | Curio
Discover Curio Originals
Plus 10,000+ audio articles from 30+ world-leading publications.
All in 1 subscription.

The business of psychedelics: Wall Street backs a new class of drugs

Stay up-to-date with the biggest stories in tech and business. Every weekday.

Connected logo
By Connected

Stay connected with the biggest global stories in business and tech. Presented by Karleen Leveille, every weekday on Curio. In today's episode... As medical investors search for more cost-effective psychedelic treatments, The Wall Street Journal reports how the fledgling industry has already been sobered. Then, could ketamine be the answer to treating alcoholism and addiction? Discover how a U.S. wellness clinic is seeing positive results from this experimental therapy with the Financial Times.

Get the best of 30+ publications for the price of one
Start your 7-day free trial